32results about How to "Ease of administration" patented technology

A secure database appliance leverages database security in a consistent framework provides consistent, flexible, and adaptable security using mandatory access controls in addition to user and role based security for access control and accountability. A database system comprises database objects having a level of security, factors representing a characteristic of a user of the database system, rules defining a limitation on operation of the database system by the user based on at least some of the plurality of factors and based on attributes of data to be operated on, including the level of security of the database object, and a plurality of realms defining a privilege of the user relative to a schema, the database system is operable to grant or deny access to data to a user based on the factors, the rules satisfied by the factors and the attributes of the data, and the realm associated with the user.

A secure database appliance leverages database security in a consistent framework provides consistent, flexible, and adaptable security using mandatory access controls in addition to user and role based security for access control and accountability. A database system communicatively connected to a plurality of network domains, each network domain having a level of security, the database system comprises at least one database accessible from all of the plurality of network domains, the database comprising data, each unit of data having a level of security and access control security operable to provide access to a unit of data in the database to a network domain based on the level of security of the network domain and based on the level of security of the unit of data.

Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and / or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

The invention relates to pharmaceutical compositions comprising α-Gal BOEL for use in treating patients with tumors. The invention also relates to methods of treating tumors using said compositions. The invention discloses that following intratumoral injection of α-Gal BOEL, binding of the natural anti-Gal antibody to de novo expressed tumoral α-Gal epitopes induces inflammation resulting in an anti-Gal antibody mediated opsonization of tumor cells and their uptake by antigen presenting cells. These antigen presenting cells migrate to draining lymph nodes and activate tumor specific T cells thereby converting the treated tumor lesions into in situ autologous tumor vaccines. This therapy can be applied to patients with multiple lesions and in neo-adjuvant therapy to patients before tumor resection. In addition to the regression and / or destruction of the treated tumor, such a vaccine will help in the immune mediated destruction of micrometastases that are not detectable during the removal of the treated tumor. The invention further teaches the enhancement of anti-tumor α-Gal BOEL treatment by the use of antibodies that inhibit the activity of immunological checkpoints molecules.

The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.

The purpose of the invention is to provide a method and a system for medical performance quantification, which make the medical performance quantification more convenient and objective. The method includes the following steps that: S1,professional thesaurus is established; S2, key-value dictionary is established, and specialized words in the professional thesaurus are assigned; S3,medical cases are segmented using the established professional thesaurus, and the medical cases are assigned scores using the key-value dictionary; S4,medical cases scores are summarized and ranked in each department. Compared with the prior art, the advantages of the method is that the system can effectively use medical data to quantify the medical performance, the quantitative results are more accurate and objective, and the quantitative processes are shorter and more efficient. The system is convenient for administrative departments of major hospitals and related units to manage the operation.

The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. Also provided are useful analytical methods utilizing these polymers to query the dynamics of blood clotting in vitro.